Quote | 89bio Inc. (NYSE:ETNB)
Last: | $ |
---|---|
Change Percent: | 2.45% |
Open: | $28.80 |
Close: | $29.30 |
High: | $31.19 |
Low: | $27.76 |
Volume: | 11,196 |
Last Trade Date Time: | 02/12/2020 04:44:06 pm |
News | 89bio Inc. (NYSE:ETNB)
2024-04-24 13:02:30 ET Summary Madrigal Pharmaceuticals, Inc. recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH. The NASH market is projected to reach $50 billion by 2035, making it a significant opportunity for Madrigal Phar...
2024-04-23 13:12:48 ET Summary The recent lack of M&A activity and rising interest rates have helped trigger an approximate 20% decline in small-cap biotech equities. Drug blockbusters facing key patent expirations and Big Pharma's surplus of cash suggest increased M&A vol...
Message Board Posts | 89bio Inc. (NYSE:ETNB)
Subject | By | Source | When |
---|---|---|---|
Very, very easy to unintentionally do in the | MiamiGent | investorshub | 06/23/2023 2:51:27 PM |
MG, I'm being told that I have you | back2basics | investorshub | 06/23/2023 2:52:57 AM |
MomentumIts trading last trade up | MiamiGent | investorshub | 06/19/2023 8:25:19 PM |
bulls and bears | BigBadWolf | investorshub | 06/19/2023 12:26:25 PM |
$ETNB Time for a bounce? | subslover | investorshub | 06/19/2023 3:54:18 AM |
News, Short Squeeze, Breakout and More Instantly...
89bio Inc. Company Name:
ETNB Stock Symbol:
NYSE Market:
2024-04-21 06:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the developme...
SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Martin Babl...